Denali Therapeutics Inc. (DNLI) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 South San Francisco, CA, 미국. 현재 CEO는 Ryan J. Watts.
DNLI 을(를) 보유 IPO 날짜 2017-12-08, 443 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $3.2B.
Denali Therapeutics Inc. is a biopharmaceutical company headquartered in South San Francisco, California, focused on discovering and developing therapeutic candidates for neurodegenerative diseases. The company's pipeline includes several clinical-stage programs, such as BIIB122/DNL151, a LRRK2 inhibitor in Phase I/Ib trials for Parkinson's disease, DNL310 for Hunter syndrome, DNL343 for ALS, and SAR443122/DNL758 for cutaneous lupus erythematosus. Denali has established strategic collaborations with leading pharmaceutical and research institutions including Takeda, Genentech, Sanofi, and Harvard University to advance its antisense therapy platform and other neurodegenerative disease treatments. The company was incorporated in 2013 and operates under its current name since March 2015.
